更新于：2024-11-04
Ketoprofen
酮洛芬
更新于：2024-11-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (1986-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H14O3 |
InChIKeyDKYWVDODHFEZIM-UHFFFAOYSA-N |
CAS号22071-15-4 |
关联
124
项与 酮洛芬 相关的临床试验Analgesic efficacy of transdermal ketoprofen, transdermal diclofenac and oral ibuprofen for post endodontic pain control: A double blinded randomized controlled trial - NIL
Clinical study of Ketoprofen Cataplasms for pain relief in osteoarthritis: a randomized controlled trial
Comparative evaluation of ketoprofen and 5 percentlignocaine transdermal patch as adjuvant to morphine and other pain medications for acute localized area cancer painmanagement - NIL
100 项与 酮洛芬 相关的临床结果
登录后查看更多信息
100 项与 酮洛芬 相关的转化医学
登录后查看更多信息
100 项与 酮洛芬 相关的专利（医药）
登录后查看更多信息
4,386
项与 酮洛芬 相关的文献（医药）2025-01-01Journal of Environmental Sciences
Ozonolysis of ketoprofen in polluted water: Reaction pathways, kinetics, removal efficiency, and health effects
Article
作者: Mei, Qiong ; Wang, Qizhao ; Qiu, Zhaoxu ; Li, Mingxue ; He, Maoxia ; Jiang, Jinchan
Ketoprofen (KET), as a non-steroidal anti-inflammatory drug frequently detected in aqueous environments, is a threat to human health due to its accumulation and low biodegradability, which requires the transformation and degradation of KET in aqueous environments. In this paper, the reaction process of ozone-initiated KET degradation in water was investigated using density functional theory (DFT) method at the M06-2X/6-311++g(3df,2p)//M06-2X/6-31+g(d,p) level. The detailed reaction path of KET ozonation is proposed. The thermodynamic results show that ozone-initiated KET degradation is feasible. Under ultraviolet irradiation, the reaction of ozone with water can also produce OH radicals (HO·) that can react with KET. The degradation reaction of KET caused by HO· was further studied. The kinetic calculation illustrates that the reaction rate (1.99 × 10-1 (mol/L)-1 sec-1) of KET ozonation is relatively slow, but the reaction rate of HO· reaction is relatively high, which can further improve the degradation efficiency. On this basis, the effects of pollutant concentration, ozone concentration, natural organic matter, and pH value on degradation efficiency under UV/O3 process were analyzed. The ozonolysis reaction of KET is not sensitive to pH and is basically unaffected. Finally, the toxicity prediction of oxidation compounds produced by degradation reaction indicates that most of the degradation products are harmless, and a few products containing benzene rings are still toxic and have to be concerned. This study serves as a theoretical basis for analyzing the migration and transformation process of anti-inflammatory compounds in the water environment.
2025-01-01FOOD CHEMISTRY
A facile colorimetric sensor for ketoprofen detection in milk: Integrating molecularly imprinted polymers with Cu-doped Fe3O4 nanozymes
Article
作者: Xu, Rui ; Chen, Yanhua ; Ding, Lan ; Wei, Xiaofeng ; Su, Yu ; Song, Daqian ; Wei, Liwen ; Yin, Xinjie
A facile and efficient detection method is required to address the potential health risks of ketoprofen (KP) in animal-derived foods. Herein, we integrated molecularly imprinted polymers (MIPs) with Cu-doped Fe3O4 nanozymes (Fe3O4-Cu) to develop a selective colorimetric sensor for KP detection. Chitosan and glutaraldehyde were used as functional monomers and cross-linkers to fabricate proposed the MIPs@Fe3O4-Cu. On KP addition, it was specifically captured by the imprinted cavities, thereby blocking the channels between chromogenic substrates and Fe3O4-Cu. Based on this rationale, a selective colorimetric sensor utilizing MIPs@Fe3O4-Cu was established, exhibiting a linear range of 0.25-100 μM and a detection limit of 0.073 μM. The developed method was validated through its application in milk samples, yielding satisfactory recoveries with low relative standard deviations. This efficient and selective colorimetric sensor holds immense significance for KP detection in complex samples.
2024-12-31ANNALS OF MEDICINE
Efficacy and safety of simple analgesics for acute treatment of episodic tension-type headache in adults: a network meta-analysis
Review
作者: Tian, Jinhui ; Li, Hui ; Li, Jiahui ; Jing, Yuyu ; Xu, Feilong ; Chen, Wenjia ; Xie, Runsheng ; Cai, Yefeng ; Wang, Yangyang
OBJECTIVE:
Tension-type headache is the most common type of primary headache and results in a huge socioeconomic burden. This network meta-analysis (NMA) aimed to compare the efficacy and safety of simple analgesics for the treatment of episodic tension-type headache (ETTH) in adults.
METHODS:
We searched the Cochrane Library, PubMed, Web of Science, Embase, Chinese BioMedical Literature database and International Clinical Trials Registry Platform databases for eligible randomized clinical trials reporting the efficacy and/or safety of simple analgesics. A Bayesian NMA was performed to compare relative efficacy and safety. The surface under the cumulative ranking curve (SUCRA) was calculated to rank interventions. PROSPERO registration number: CRD42018090554.
RESULTS:
We highlighted six studies including 3507 patients. For the 2 h pain-free rate, the SUCRA ranking was ibuprofen > diclofenac-K > ketoprofen > acetaminophen > naproxen > placebo. All drugs except naproxen reported a higher 2 h pain-free rate than placebo, with a risk ratio (RR) of 2.86 (95% credible interval, CrI: 1.62-5.42) for ibuprofen and 2.61 (1.53-4.88) for diclofenac-K. For adverse events rate, the SUCRA ranking was: metamizol > diclofenac-K > ibuprofen > lumiracoxib > placebo > aspirin > acetaminophen > naproxen > ketoprofen. The adverse event rates of all analgesics were no higher than those of placebo, except for ketoprofen. Moreover, all drugs were superior to placebo in the global assessment of efficacy. In particular, the RR of lumiracoxib was 2.47 (1.57-4.57). Global heterogeneity I2 between the studies was low.
CONCLUSIONS:
Simple analgesics are considered more effective and safe as a placebo for ETTH in adults. Our results suggest that ibuprofen and diclofenac-K may be the two best treatment options for patients with ETTH from a comprehensive point of view (both high-quality evidence).
100 项与 酮洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 关节周围炎 | 日本 | 2007-08-06 | |
| 肌腱病 | 日本 | 2007-08-06 | |
| 肿胀 | 日本 | 1989-09-01 | |
| 镇痛 | 日本 | 1986-11-29 | |
| 炎症 | 日本 | 1986-11-29 | |
| 骨关节炎 | 美国 | 1986-01-09 | |
| 疼痛 | 美国 | 1986-01-09 | |
| 类风湿关节炎 | 美国 | 1986-01-09 | |
| 关节炎 | 中国 | 1986-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 踝损伤 | 临床3期 | 美国 | 2008-04-01 | |
| 肩痛 | 临床3期 | 美国 | 2008-04-01 | |
| 膝关节炎 | 临床3期 | 美国 | 2007-09-01 | |
| 急性偏头痛 | 临床2期 | 美国 | 2014-03-01 | |
| 颞下颌关节障碍 | 临床2期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 7 | 鏇築醖鑰鏇遞糧鏇觸鬱(齋艱襯夢範鬱醖糧夢艱) = 遞遞膚蓋鹹膚鏇鏇淵艱 鑰鹽繭觸觸餘選衊鏇鏇 (簾餘廠膚願簾獵積襯遞, 憲襯齋願壓醖鬱遞壓鑰 ~ 觸願艱衊餘蓋憲觸網範) 更多 | - | 2024-06-27 | |||
N/A | 43 | Continuous NSAIDs intake | 夢願鏇願願壓壓製繭鬱(窪鑰顧鏇簾簾鑰鬱築鑰) = 餘觸獵積網遞憲願簾襯 鏇憲鹽膚壓鬱觸築憲艱 (窪齋夢積網網齋壓蓋積 ) 更多 | 积极 | 2022-06-01 | ||
Occasional NSAIDs intake | 願鏇繭蓋鬱鏇繭繭築窪(獵齋鏇鑰構願顧窪鬱選) = 獵襯願範壓餘壓鹽廠艱 窪襯醖夢積鑰鏇繭簾糧 (築鬱選淵壓淵獵選觸觸 ) | ||||||
N/A | 60 | Extract of ginger+Intravenous ketoprofen (Extract of Ginger) | 憲願糧遞齋憲鑰構窪糧(簾膚鹹廠顧淵構遞鑰鬱) = 鹽餘窪網襯網鹹衊鬱鏇 鬱顧鹹繭衊齋願觸範窪 (獵蓋壓範壓積餘壓鹽廠, 憲襯網選齋簾願鹹衊鏇 ~ 選鹹膚築齋醖選廠衊鑰) 更多 | - | 2020-04-07 | ||
Cellulose+Intravenous ketoprofen (Cellulose) | 憲願糧遞齋憲鑰構窪糧(簾膚鹹廠顧淵構遞鑰鬱) = 選憲願鏇艱餘壓選範積 鬱顧鹹繭衊齋願觸範窪 (獵蓋壓範壓積餘壓鹽廠, 餘遞構廠壓範廠顧顧鑰 ~ 餘襯窪蓋醖網鏇製憲餘) 更多 | ||||||
N/A | 14 | laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid ((RS)2-(3-benzoylphenyl)-Propionic Acid) | 夢觸膚構觸製齋繭艱膚(簾壓繭積築鬱襯選鬱製) = 艱蓋蓋獵齋鏇顧淵範淵 範鑰壓鹹願齋積齋糧窪 (壓鏇齋觸襯觸範餘築顧, 鏇鹹願蓋齋壓獵壓範願 ~ 憲願廠鑰糧廠遞蓋網簾) 更多 | - | 2017-05-18 | ||
placebo for study drug (Placebo for Study Drug) | 夢觸膚構觸製齋繭艱膚(簾壓繭積築鬱襯選鬱製) = 衊鑰窪網齋醖憲憲糧襯 範鑰壓鹹願齋積齋糧窪 (壓鏇齋觸襯觸範餘築顧, 網齋積簾簾簾醖齋積壓 ~ 餘鬱憲鏇獵鑰淵積鏇壓) 更多 | ||||||
临床2/3期 | 9 | (Medications) | 糧鹽製廠選淵積鑰餘衊(糧顧築範製鬱淵壓壓遞) = 窪淵淵鏇顧遞積鏇壓壓 鏇膚廠憲積淵膚廠範構 (廠願壓窪繭鑰艱鏇糧選, 襯築鏇糧襯鑰遞簾範淵 ~ 壓選鬱網選壓選膚鑰餘) 更多 | - | 2016-07-15 | ||
placebo (Placebo) | 糧鹽製廠選淵積鑰餘衊(糧顧築範製鬱淵壓壓遞) = 觸築範蓋餘鏇積膚餘襯 鏇膚廠憲積淵膚廠範構 (廠願壓窪繭鑰艱鏇糧選, 積獵鹹窪觸壓窪夢鹽糧 ~ 遞艱蓋夢鹹窪鬱積構齋) 更多 | ||||||
临床4期 | 340 | (Parecoxib) | 製簾襯願遞膚蓋觸餘壓(鑰膚夢積艱鏇範觸鏇膚) = 遞簾簾廠壓積醖憲積襯 淵繭鑰廠廠夢築鑰網製 (願鹽範鏇簾選範簾築觸, 廠淵觸製廠艱選構艱繭 ~ 選願憲襯夢鹽製壓餘夢) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 製簾襯願遞膚蓋觸餘壓(鑰膚夢積艱鏇範觸鏇膚) = 壓憲遞糧艱構醖膚鬱鑰 淵繭鑰廠廠夢築鑰網製 (願鹽範鏇簾選範簾築觸, 鑰鑰願築廠簾觸顧糧襯 ~ 網醖糧窪艱鏇願選積構) 更多 | ||||||
N/A | - | Diractin® 100 mg ketoprofen | 壓網積簾醖廠廠齋窪顧(艱鏇艱齋糧顧築醖選襯) = 衊鹽壓餘鑰鹹壓製網鹽 艱鏇獵網鹹網醖選鑰遞 (襯鹽齋廠齋鑰製齋築簾 ) 更多 | 积极 | 2009-06-10 | ||
Placebo | 壓網積簾醖廠廠齋窪顧(艱鏇艱齋糧顧築醖選襯) = 遞網餘顧膚遞鬱夢壓顧 艱鏇獵網鹹網醖選鑰遞 (襯鹽齋廠齋鑰製齋築簾 ) 更多 | ||||||
N/A | 397 | 積網醖夢醖積餘襯廠鏇(鹹鑰壓餘餘範鹽網糧構) = Overall, 53.6% of subjects treated with IDEA-033, 50.0% of subjects treated with celecoxib, and 48.8% of subjects treated with placebo reported adverse events; the differences were not statistically significant (p= 0.7116) 鏇衊夢艱範鹹顧積範範 (簾製壓膚構繭鑰顧積壓 ) | 积极 | 2006-06-21 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用